drugset / Trial / NCT06627088
A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants
Phase 1
Completed
24 enrolled
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The study has two parts, Part A and Part B. The purpose of Part A is to determine the absorption, metabolism, and excretion (AME) of \[14C\]-LY4100511 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants after a single oral dose of LY4100511. The purpose of Part B is to determine the absolute bioavailability of LY4100511 in humans, to further analyze the rate and routes of excretion, including the mass balance, and to further investigate the pharmacokinetics (PK) of \[14C\]-LY4100511, LY4100511, and TRA.
Timeline
- Start
- 2024-08-23
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY4100511 | Unknown | 0.037 mbq | Oral |
| Subject | LY4100511 | Unknown | 3.7 mbq | Oral |
Indications
No indication recorded.